Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Bms 742413
2. Bms-742413
3. N-(3-(7-methyl-1h-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl))-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide
1. Vazegepant
2. Bms-742413
3. Bhv-3500
4. Zavegepant [usan]
5. Odu3zaz94j
6. Bms-742413-01
7. 1337918-83-8
8. Chembl2397415
9. N-[(2r)-3-(7-methyl-1h-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1h-quinolin-3-yl)piperidine-1-carboxamide
10. 1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-
11. 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-1-piperidinecarboxamide
12. Zavegepant [inn]
13. Unii-odu3zaz94j
14. Vazegepant [who-dd]
15. Schembl107428
16. Gtpl11513
17. Ex-a6698
18. Bdbm50436107
19. Bms742413
20. Who 11512
21. Hy-134992
22. Cs-0168642
| Molecular Weight | 638.8 g/mol |
|---|---|
| Molecular Formula | C36H46N8O3 |
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 638.36928736 g/mol |
| Monoisotopic Mass | 638.36928736 g/mol |
| Topological Polar Surface Area | 117 Ų |
| Heavy Atom Count | 47 |
| Formal Charge | 0 |
| Complexity | 1160 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : ZAVZPRET
Dosage Form : SPRAY, METERED;NASAL
Dosage Strength : EQ 10MG BASE/SPRAY
Approval Date : 2023-03-09
Application Number : 216386
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
99
PharmaCompass offers a list of Zavegepant HCl API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Zavegepant HCl manufacturer or Zavegepant HCl supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Zavegepant HCl manufacturer or Zavegepant HCl supplier.
PharmaCompass also assists you with knowing the Zavegepant HCl API Price utilized in the formulation of products. Zavegepant HCl API Price is not always fixed or binding as the Zavegepant HCl Price is obtained through a variety of data sources. The Zavegepant HCl Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Vazegepant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vazegepant, including repackagers and relabelers. The FDA regulates Vazegepant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vazegepant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Vazegepant manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Vazegepant supplier is an individual or a company that provides Vazegepant active pharmaceutical ingredient (API) or Vazegepant finished formulations upon request. The Vazegepant suppliers may include Vazegepant API manufacturers, exporters, distributors and traders.
click here to find a list of Vazegepant suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Vazegepant DMF (Drug Master File) is a document detailing the whole manufacturing process of Vazegepant active pharmaceutical ingredient (API) in detail. Different forms of Vazegepant DMFs exist exist since differing nations have different regulations, such as Vazegepant USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Vazegepant DMF submitted to regulatory agencies in the US is known as a USDMF. Vazegepant USDMF includes data on Vazegepant's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Vazegepant USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Vazegepant suppliers with USDMF on PharmaCompass.
A Vazegepant written confirmation (Vazegepant WC) is an official document issued by a regulatory agency to a Vazegepant manufacturer, verifying that the manufacturing facility of a Vazegepant active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Vazegepant APIs or Vazegepant finished pharmaceutical products to another nation, regulatory agencies frequently require a Vazegepant WC (written confirmation) as part of the regulatory process.
click here to find a list of Vazegepant suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Vazegepant as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Vazegepant API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Vazegepant as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Vazegepant and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Vazegepant NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Vazegepant suppliers with NDC on PharmaCompass.
Vazegepant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vazegepant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vazegepant GMP manufacturer or Vazegepant GMP API supplier for your needs.
A Vazegepant CoA (Certificate of Analysis) is a formal document that attests to Vazegepant's compliance with Vazegepant specifications and serves as a tool for batch-level quality control.
Vazegepant CoA mostly includes findings from lab analyses of a specific batch. For each Vazegepant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vazegepant may be tested according to a variety of international standards, such as European Pharmacopoeia (Vazegepant EP), Vazegepant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vazegepant USP).